Anti-TBXAS1 / Thromboxane-A synthase 1

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. TBXAS1 antibody detects Thromboxane-A synthase 1, encoded by the TBXAS1 gene on chromosome 7q34. TBXAS1 antibody is used to study this cytochrome P450 enzyme responsible for producing thromboxane A2 from prostaglandin H2. Thromboxane A2 is a potent lipid mediator with strong effects on platelet aggregation, vasoconstriction, and hemostasis. TBXAS1 is predominantly expressed in platelets, vascular endothelium, and kidney, but is also found in other tissues where prostaglandin metabolism occurs. Its enzymatic activity places it at the intersection of cardiovascular physiology and inflammatory signaling.Structurally, TBXAS1 is a membrane-associated cytochrome P450 protein anchored in the endoplasmic reticulum. It possesses a heme prosthetic group essential for catalysis and shares homology with other P450 enzymes. TBXAS1 specifically rearranges prostaglandin H2 to form thromboxane A2, which is chemically unstable and rapidly hydrolyzes to thromboxane B2. This catalytic specificity is crucial for controlling thromboxane-dependent pathways in platelets and vascular smooth muscle cells.Functionally, TBXAS1 plays essential roles in hemostasis and cardiovascular regulation. By generating thromboxane A2, it drives platelet aggregation and vasoconstriction, contributing to clot formation and vascular tone. Dysregulation of TBXAS1 activity leads to pathological thrombus formation, hypertension, and atherosclerosis. TBXAS1 also influences inflammatory signaling by modulating prostanoid balance. Researchers use TBXAS1 antibody to measure its expression in studies of platelet biology, vascular disease, and inflammatory processes.Clinically, mutations in TBXAS1 cause Ghosal hematodiaphyseal dysplasia, a rare bone marrow failure syndrome with skeletal abnormalities and anemia. Overexpression or increased activity of TBXAS1 contributes to cardiovascular disease risk by promoting platelet hyperactivity and vasoconstriction. Pharmacological inhibition of TBXAS1 reduces thromboxane A2 production and is clinically exploited by aspirin and related drugs that block upstream cyclooxygenase activity. Elevated TBXAS1 expression has also been observed in certain cancers, where it may support tumor growth by influencing angiogenesis and platelet-tumor interactions.Experimentally, TBXAS1 antibody is used in western blotting to detect the ~60 kDa protein, in immunohistochemistry to assess vascular and platelet expression, and in ELISA to quantify protein levels. Immunoprecipitation with TBXAS1 antibody helps analyze enzyme complexes in prostaglandin metabolism. NSJ Bioreagents supplies TBXAS1 antibody for research into platelet function, vascular biology, and inflammatory signaling.